Sanara Medtech Inc (SMTI) - Total Liabilities

Latest as of December 2025: $67.01 Million USD

Based on the latest financial reports, Sanara Medtech Inc (SMTI) has total liabilities worth $67.01 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SMTI cash generation efficiency to assess how effectively this company generates cash.

Sanara Medtech Inc - Total Liabilities Trend (1999–2025)

This chart illustrates how Sanara Medtech Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Sanara Medtech Inc to evaluate the company's liquid asset resilience ratio.

Sanara Medtech Inc Competitors by Total Liabilities

The table below lists competitors of Sanara Medtech Inc ranked by their total liabilities.

Company Country Total Liabilities
Shriram Properties Limited
NSE:SHRIRAMPPS
India Rs27.51 Billion
Kimia Farma Persero Tbk
JK:KAEF
Indonesia Rp11.91 Trillion
Intelligent Monitoring Group Ltd
AU:IMB
Australia AU$157.42 Million
HyVision System. Inc
KQ:126700
Korea ₩50.51 Billion
Orion Minerals Ltd
AU:ORN
Australia AU$59.95 Million
Antony Waste Handling Cell Limited
NSE:AWHCL
India Rs8.38 Billion
Groupe Sfpi
PA:SFPI
France €317.26 Million
Surya Fajar Capital Tbk PT
JK:SFAN
Indonesia Rp70.66 Billion

Liability Composition Analysis (1999–2025)

This chart breaks down Sanara Medtech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sanara Medtech Inc (SMTI) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.80 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 11.30 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.92 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sanara Medtech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sanara Medtech Inc (1999–2025)

The table below shows the annual total liabilities of Sanara Medtech Inc from 1999 to 2025.

Year Total Liabilities Change
2025-12-31 $67.01 Million +36.26%
2024-12-31 $49.18 Million +67.95%
2023-12-31 $29.28 Million +51.61%
2022-12-31 $19.32 Million +209.32%
2021-12-31 $6.24 Million +56.66%
2020-12-31 $3.99 Million -15.64%
2019-12-31 $4.72 Million +144.81%
2018-12-31 $1.93 Million -8.76%
2017-12-31 $2.12 Million -18.46%
2016-12-31 $2.59 Million -2.58%
2015-12-31 $2.66 Million +14.60%
2014-12-31 $2.32 Million -32.56%
2013-12-31 $3.45 Million -33.73%
2012-12-31 $5.20 Million -32.41%
2011-12-31 $7.69 Million +96.51%
2010-12-31 $3.91 Million +59.28%
2009-12-31 $2.46 Million +419.61%
2008-12-31 $472.97K -78.69%
2007-12-31 $2.22 Million +25.59%
2006-12-31 $1.77 Million +95.22%
2005-12-31 $905.27K +458.02%
2004-12-31 $162.23K -95.44%
2001-12-31 $3.56 Million +41.53%
2000-12-31 $2.52 Million +37.64%
1999-12-31 $1.83 Million --

About Sanara Medtech Inc

NASDAQ:SMTI USA Medical Instruments & Supplies
Market Cap
$180.87 Million
Market Cap Rank
#17497 Global
#3933 in USA
Share Price
$19.73
Change (1 day)
+3.90%
52-Week Range
$16.34 - $35.75
All Time High
$52.75
About

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and seco… Read more